Thalidomide as an emerging immunotherapeutic agent.
Marriott
J B
JB
Division of Oncology, Dept of Cellular and Molecular Sciences, St George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK. jmarriot@sghms.ac.uk
Muller
G
G
Dalgleish
A G
AG
D000014:Abnormalities, Drug-Induced / Q000209:etiology; D000163:Acquired Immunodeficiency Syndrome / Q000628:therapy; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D015195:Drug Design; D004893:Erythema Nodosum / Q000209:etiology / Q000628:therapy; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D015440:Leprosy, Lepromatous / Q000150:complications; D009369:Neoplasms / Q000628:therapy; D009389:Neovascularization, Pathologic / Q000628:therapy; D018418:Th2 Cells / Q000187:drug effects / Q000378:metabolism; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000276:Adjuvants, Immunologic; D000894:Anti-Inflammatory Agents, Non-Steroidal; D014409:Tumor Necrosis Factor-alpha; D013792:Thalidomide